{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 461093505
| IUPAC_name = 4-Methoxy-''N''-[2-(1-methyl-2-piperidin-1-ylethyl)phenyl]benzamide
| image = Encainide.svg

<!--Clinical data-->
| tradename = Enkaid
| Drugs.com = {{drugs.com|CONS|encainide}}
| MedlinePlus = a605040
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_category =
| legal_AU = <!-- Unscheduled / S2 / S4 / S8 -->
| legal_UK = <!-- GSL / P / POM / CD -->
| legal_US = <!-- OTC / Rx-only -->
| legal_status = Withdrawn
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability =
| protein_bound =
| metabolism =
| elimination_half-life =
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 66778-36-7
| ATC_prefix = C01
| ATC_suffix = BC08
| ATC_supplemental =
| PubChem = 48041
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
 | DrugBank = DB01228
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 315838
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 43697
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = SY3J0147NB
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D07894
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 4788

<!--Chemical data-->
| C=22 | H=28 | N=2 | O=2
| molecular_weight = 352.47 g/mol
| smiles = CN1CCCCC1CCC2=CC=CC=C2NC(=O)C3=CC=C(C=C3)OC
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C22H28N2O2/c1-24-16-6-5-8-19(24)13-10-17-7-3-4-9-21(17)23-22(25)18-11-14-20(26-2)15-12-18/h3-4,7,9,11-12,14-15,19H,5-6,8,10,13,16H2,1-2H3,(H,23,25)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = PJWPNDMDCLXCOM-UHFFFAOYSA-N
}}

'''Encainide''' (trade name '''Enkaid''') is a class Ic [[antiarrhythmic agent]]. It is no longer used because of its frequent [[proarrhythmic]] side effects.<ref>{{Cite journal
| last1 = Echt | first1 = D. S.
| last2 = Liebson | first2 = P. R.
| last3 = Mitchell | first3 = L. B.
| last4 = Peters | first4 = R. W.
| last5 = Obias-Manno | first5 = D.
| last6 = Barker | first6 = A. H.
| last7 = Arensberg | first7 = D.
| last8 = Baker | first8 = A.
| last9 = Friedman | first9 = L.
| last10 = Greene
| doi = 10.1056/NEJM199103213241201 | first10 = H. L.
| last11 = Huther | first11 = M. L.
| last12 = Richardson | first12 = D. W.
| title = Mortality and Morbidity in Patients Receiving Encainide, Flecainide, or Placebo
| journal = New England Journal of Medicine
| volume = 324
| issue = 12
| pages = 781–788
| year = 1991
| pmid = 1900101
| pmc =
}}</ref>

==Synthesis==
[[File:Encainide synthesis.png|thumb|700px|center|Encainide synthesis:<ref>S.J. Dykstra, J.L. Minelli, {{Cite patent|DE|2210154}} (1972).</ref><ref>S.J. Dykstra, J.L. Minelli, {{US Patent|3931195}} (1976).</ref><ref>{{cite journal | doi = 10.1021/jm00267a012 | pmid=4745503 | title=Lysergic acid and quinidine analogs. 2-(o-Acylaminophenethyl)piperidines | journal=Journal of Medicinal Chemistry | date=1973 | volume=16 | issue=9 | pages=1015–1020 | first=Stanley J. | last=Dykstra}}</ref>]]

==See also==
* [[Cardiac Arrhythmia Suppression Trial]]

==References==
{{reflist}}

{{Sodium channel blockers}}
{{Antiarrhythmic agents}}

[[Category:Antiarrhythmic agents]]
[[Category:Benzanilides]]
[[Category:Phenol ethers]]
[[Category:Piperidines]]
[[Category:Sodium channel blockers]]
[[Category:Withdrawn drugs]]

{{cardiovascular-drug-stub}}